News & Press Releases

Access the latest news about Lipidor, our current projects, publications and collaborations. Thank you for your interest in Lipidor!

Subscribe

May 22, 2024

Lipidor AB (publ) publishes interim report for Q1 2024

STOCKHOLM, Sweden, 22 May 2024 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the period January – March 2024. The report is available on the company's website lipidor.se and in the attached pdf. To read the quarterly report (in Swedish) click here:…

May 21, 2024

Bulletin from the Extraordinary General Meeting of Lipidor AB (publ)

The following resolutions were passed at the Extraordinary General Meeting (the “EGM”) of Lipidor AB (publ) (the “Company”) on 21 May 2024…

May 15, 2024

Lipidor AB (publ) publishes annual report for 2023

STOCKHOLM, Sweden, 15th May 2024 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its annual report for the…

May 7, 2024

NOTICE OF ANNUAL GENERAL MEETING IN LIPIDOR AB (PUBL)

The shareholders of Lipidor AB (publ) reg. no. 556779-7500 (the “Company”) are hereby given notice to attend the Annual General Meeting (the…

April 22, 2024

Lipidor AB announces new date for publication of Annual Report 2023

Lipidor AB (publ) today announces that the Board of Directors has resolved to postpone the publication of the Annual Report for 2023…

April 10, 2024

NOTICE OF EXTRAORDINARY GENERAL MEETING IN LIPIDOR AB (PUBL)

The shareholders of Lipidor AB (publ) reg. no. 556779-7500 (the “Company”) are hereby given notice to attend the Extraordinary General Meeting (the…

April 10, 2024

Lipidor resolves on a rights issue of approximately SEK 58.0 million and enters into a co-investment agreement which secures funding for the implementation of the upcoming phase III study

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW…

March 26, 2024

Lipidor completes planned divestment of shares in Emollivet

STOCKHOLM, Sweden, 26th March 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the remaining holding of…

March 21, 2024

Lipidor announces approval for start of Phase III clinical trial of psoriasis candidate AKP02G2

STOCKHOLM, Sweden, 21st March 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announced that the company's planned Phase…

March 6, 2024

Lipidor adds capital through sale of shares

STOCKHOLM, Sweden, 6th March 2024 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces that 100 Emollivet shares, corresponding…

February 28, 2024

Lipidor AB (publ) publishes year-end report for 2023

STOCKHOLM, Sweden, 28th February 2024 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its year-end report for the…